[go: up one dir, main page]

HUP9900609A2 - Cefditoren pivoxilt tartalmazó, orálisan beadható antibakteriális kompozíció - Google Patents

Cefditoren pivoxilt tartalmazó, orálisan beadható antibakteriális kompozíció

Info

Publication number
HUP9900609A2
HUP9900609A2 HU9900609A HUP9900609A HUP9900609A2 HU P9900609 A2 HUP9900609 A2 HU P9900609A2 HU 9900609 A HU9900609 A HU 9900609A HU P9900609 A HUP9900609 A HU P9900609A HU P9900609 A2 HUP9900609 A2 HU P9900609A2
Authority
HU
Hungary
Prior art keywords
stone
water
cefditoren pivoxil
oral administration
composition
Prior art date
Application number
HU9900609A
Other languages
English (en)
Inventor
Kenichi Abe
Toshihiro Kikkoji
Chikako Murakami
Masato Ota
Hiroyuki Yamaguchi
Original Assignee
Meiji Seika Kaisha, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha, Ltd. filed Critical Meiji Seika Kaisha, Ltd.
Publication of HUP9900609A2 publication Critical patent/HUP9900609A2/hu
Publication of HUP9900609A3 publication Critical patent/HUP9900609A3/hu
Publication of HU224922B1 publication Critical patent/HU224922B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány őrális beadásra alkalmas új, antibakteriális kőmpőzícióravőnatkőzik, amely cefditőren pivőxil és egy vízőldható kazeinsókeverékét tartalmazza. A kőmpőzícióból, amelyben gyengébb a cefditőrenpivőxil keserű íze, a cefditőren pivőxil vízben könnyebben őldódik ki,és nagyőbb százalékős kiőldódás érhető el a cefditőren pivőxil vízzelvaló kiőldásakőr. A kőmpőzíció őrális beadásakőr a cefditőrenkőmpőnensnagymértékben felszívódik az emésztőcsatőrnában. A kőmpőzícióban acefditőren pivőxil - kazeinsó tömegarány előnyösen 1 : 0,1 és 1 : 4közötti. A találmány másődik váltőzata szerint az előbbi kőmpőzíciótővábbi összetevőként egy vízőldható pőlifőszfőrsavas sót tartalmaz.Ezáltal a cefditőrenpivőxil-kőmpőnens nagymértékű vízőldhatósága akkőris megmarad, ha a kőmpőzíciót szélsőséges körülmények között tárőlják. ŕ
HU9900609A 1995-10-13 1996-10-14 Antibacterial composition of cefditoren pivoxil for oral administration HU224922B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26584795 1995-10-13
PCT/JP1996/002967 WO1997013516A1 (fr) 1995-10-13 1996-10-14 Composition antibacterienne administree par voie orale

Publications (3)

Publication Number Publication Date
HUP9900609A2 true HUP9900609A2 (hu) 1999-07-28
HUP9900609A3 HUP9900609A3 (en) 2001-04-28
HU224922B1 HU224922B1 (en) 2006-04-28

Family

ID=17422903

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900609A HU224922B1 (en) 1995-10-13 1996-10-14 Antibacterial composition of cefditoren pivoxil for oral administration

Country Status (16)

Country Link
US (1) US5958915A (hu)
EP (1) EP0862915B1 (hu)
KR (1) KR100311576B1 (hu)
CN (1) CN1102046C (hu)
AR (1) AR004014A1 (hu)
AT (1) ATE214930T1 (hu)
BR (1) BR9610836A (hu)
CA (1) CA2234426C (hu)
DE (1) DE69620220T2 (hu)
ES (1) ES2174109T3 (hu)
HK (1) HK1016477A1 (hu)
HU (1) HU224922B1 (hu)
MX (1) MX9802849A (hu)
PT (1) PT862915E (hu)
TW (1) TW458778B (hu)
WO (1) WO1997013516A1 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL194097B1 (pl) * 1998-01-07 2007-04-30 Meiji Seika Kaisha Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania
KR100812832B1 (ko) * 1998-11-02 2008-03-11 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AU2002224053A1 (en) * 2000-11-21 2002-06-03 Kyorin Pharmaceutical Co. Ltd. Dry syrup preparations
JP4334869B2 (ja) * 2000-12-01 2009-09-30 協和発酵キリン株式会社 溶解性または経口吸収性の改善された組成物
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
EP1401402B1 (en) 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
JP4743684B2 (ja) * 2002-05-22 2011-08-10 塩野義製薬株式会社 難水溶性薬物の溶出性を改善する方法
AUPS303202A0 (en) * 2002-06-20 2002-07-11 Pacific Biolink Pty Limited Protein based oral lubricant
WO2004030673A1 (ja) * 2002-10-02 2004-04-15 Meiji Seika Kaisha, Ltd. 経口吸収性が改善された抗菌性医薬組成物
ES2379631T3 (es) * 2003-10-08 2012-04-30 Meiji Seika Pharma Co., Ltd. Composición antibacteriana no cristalina que contiene cefditoren pivoxilo
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
DE602005025682D1 (de) 2004-11-16 2011-02-10 3M Innovative Properties Co Dentalfüllstoffe und zusammensetzungen mit phosphatsalzen
KR20070086324A (ko) 2004-11-16 2007-08-27 쓰리엠 이노베이티브 프로퍼티즈 컴파니 칼슘과 인을 방출하는 유리를 함유한 치과용 조성물
WO2006055329A2 (en) 2004-11-16 2006-05-26 3M Innovative Properties Company Dental fillers including a phosphorus-containing surface treatment
CN102327194B (zh) * 2004-11-16 2014-07-23 3M创新有限公司 包括酪蛋白酸盐的牙科组合物和制备牙科制品的方法
DE112006001606T5 (de) 2005-06-08 2009-07-09 Elan Pharma International Ltd., Athlone Nanopartikuläre und eine kontrollierte Freisetzung aufweisende Zusammensetzung, die Cefditoren umfassen
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
WO2010068359A1 (en) 2008-12-11 2010-06-17 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
TR201000688A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
WO2012010938A2 (en) * 2010-07-23 2012-01-26 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
EP3244879A1 (en) 2015-01-16 2017-11-22 Ögün, Yusuf Toktamis Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105663058A (zh) * 2016-02-01 2016-06-15 济南康和医药科技有限公司 一种头孢妥仑匹酯纳米粒药物制剂及制备方法
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936609A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS59184122A (ja) * 1983-03-31 1984-10-19 Nitto Electric Ind Co Ltd アクリル系膏体
JPS60102168A (ja) * 1983-11-08 1985-06-06 Tsukishima Shokuhin Kogyo Kk エイコサペンタエン酸強化乳化物及び食品の製造方法
IE58487B1 (en) * 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH0635394B2 (ja) * 1989-02-28 1994-05-11 雪印乳業株式会社 薬物の溶解性および吸収性の改善方法
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤

Also Published As

Publication number Publication date
DE69620220D1 (de) 2002-05-02
HU224922B1 (en) 2006-04-28
CN1102046C (zh) 2003-02-26
EP0862915B1 (en) 2002-03-27
ES2174109T3 (es) 2002-11-01
WO1997013516A1 (fr) 1997-04-17
BR9610836A (pt) 1999-07-13
AR004014A1 (es) 1998-09-30
KR19990064137A (ko) 1999-07-26
ATE214930T1 (de) 2002-04-15
HUP9900609A3 (en) 2001-04-28
PT862915E (pt) 2002-09-30
TW458778B (en) 2001-10-11
HK1016477A1 (en) 1999-11-05
CA2234426C (en) 2003-07-08
US5958915A (en) 1999-09-28
DE69620220T2 (de) 2002-11-28
MX9802849A (es) 1998-11-30
EP0862915A4 (en) 1998-11-11
KR100311576B1 (ko) 2001-12-28
EP0862915A1 (en) 1998-09-09
CN1202110A (zh) 1998-12-16
CA2234426A1 (en) 1997-04-17

Similar Documents

Publication Publication Date Title
HUP9900609A2 (hu) Cefditoren pivoxilt tartalmazó, orálisan beadható antibakteriális kompozíció
BR9916835A (pt) Composição de galantamina de liberação controlada
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
BG104644A (en) Novel macrolides
RU96120090A (ru) Сублингвальная или трансбуккальная фармацевтическая композиция
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
PL348492A1 (en) Novel alpha-crystalline form of t-butylamine salt of perindopril, method of obtaining same and pharmacological compositions containing it
HUP0201907A2 (hu) Időzített kettős hatóanyag-leadású dózisformák, amelyek rövid ideig ható altatót vagy annak sóját tartalmazzák
HUP0001922A2 (hu) Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra
WO2003000692A3 (en) Oxytocin agonists
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
MY119090A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
IL41686A (en) Taste-improving formulations of oral penicillins
HUP0002106A2 (hu) Transz-5-klór-2,3,3a,12b-tetrahidro-2-metil-1H-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol aromás szulfonátjai és az ezt tartalmazó gyógyszerkészítmények
BR0104358A (pt) Formulações de taxana tendo solubilidade aperfeiçoada
EP1285660A4 (en) ZINC SUPPLEMENTARY COMPOSITIONS FOR ORAL ADMINISTRATION
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
CA2477773A1 (en) A stable diclofenac-tromethamine composition for the topical treatment of oropharyngeal cavity disorders
FR2678836B1 (fr) Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses.
ES2162856T3 (es) Derivados de ergolina serotoninergicos.
HUP9904327A2 (hu) Kinupristint és dalfopristint tartalmazó gyógyszerkészítmények és eljárás előállításukra

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MEIJI SEIKA PHARMA CO., LTD., JP

Free format text: FORMER OWNER(S): MEIJI SEIKA KAISHA, LTD., JP